EODData

MEMBERSHIP REGISTER LOG IN

FRA, GE9: Genmab A/S

05 Nov 2025
LAST:

248.9

CHANGE:
 3.70		OPEN:
249.2		HIGH:
249.2		ASK:
0.0		VOLUME:
0
CHG(%):
1.51		PREV:
245.2		LOW:
248.9		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 25249.2249.2248.9248.90
04 Nov 25245.2245.2245.2245.20
03 Nov 25246.7247.3246.7247.30
31 Oct 25244.3246.8244.3246.31
30 Oct 25247.5247.5244.7244.70
29 Oct 25248.8248.8247.3247.30
28 Oct 25248.6248.7248.6248.70
27 Oct 25252.6252.6248.6248.697
24 Oct 25256.1256.1255.7255.70
23 Oct 25255.9260.0255.3255.341

COMPANY PROFILE

Name:Genmab A/S
About:Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Address:Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
Website:https://www.genmab.com
ISIN:DK0010272202
LEI:529900MTJPDPE4MHJ122

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:50.46 
Forward P/E:31.56 
PEG Ratio:31.56 
Price to Sales:4.15 
Price to Book:2.84 
Profit Margin:0.38 
Operating Margin:0.39 
Return on Assets:0.13 
Return on Equity:0.28 
Revenue:3.165B 
EBITDA:1.152B 
Shares:61.49M 
Market Cap:15.305B 

TECHNICAL INDICATORS

MA5:246.481.0%
MA10:248.800.0%
MA20:260.774.8%
MA50:249.940.4%
MA100:218.9213.7%
MA200:202.9922.6%
STO9:36.84
STO14:11.23 
RSI14:15.43 
WPR14:-88.77 
MTM14:-33.20
ROC14:-0.12 
ATR:4.44 
Week High:249.200.1%
Week Low:244.301.9%
Month High:285.1014.5%
Month Low:244.3022.6%
Year High:285.1014.5%
Year Low:154.8460.8%
Volatility:27.17